172 related articles for article (PubMed ID: 28679043)
1. Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.
Ellermann M; Eheim A; Rahm F; Viklund J; Guenther J; Andersson M; Ericsson U; Forsblom R; Ginman T; Lindström J; Silvander C; Trésaugues L; Giese A; Bunse S; Neuhaus R; Weiske J; Quanz M; Glasauer A; Nowak-Reppel K; Bader B; Irlbacher H; Meyer H; Queisser N; Bauser M; Haegebarth A; Gorjánácz M
ACS Chem Biol; 2017 Aug; 12(8):1986-1992. PubMed ID: 28679043
[TBL] [Abstract][Full Text] [Related]
2. Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design.
Rahm F; Viklund J; Trésaugues L; Ellermann M; Giese A; Ericsson U; Forsblom R; Ginman T; Günther J; Hallberg K; Lindström J; Persson LB; Silvander C; Talagas A; Díaz-Sáez L; Fedorov O; Huber KVM; Panagakou I; Siejka P; Gorjánácz M; Bauser M; Andersson M
J Med Chem; 2018 Mar; 61(6):2533-2551. PubMed ID: 29485874
[TBL] [Abstract][Full Text] [Related]
3. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival.
Kawamura T; Kawatani M; Muroi M; Kondoh Y; Futamura Y; Aono H; Tanaka M; Honda K; Osada H
Sci Rep; 2016 May; 6():26521. PubMed ID: 27210421
[TBL] [Abstract][Full Text] [Related]
4. Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
[TBL] [Abstract][Full Text] [Related]
5. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.
Gad H; Koolmeister T; Jemth AS; Eshtad S; Jacques SA; Ström CE; Svensson LM; Schultz N; Lundbäck T; Einarsdottir BO; Saleh A; Göktürk C; Baranczewski P; Svensson R; Berntsson RP; Gustafsson R; Strömberg K; Sanjiv K; Jacques-Cordonnier MC; Desroses M; Gustavsson AL; Olofsson R; Johansson F; Homan EJ; Loseva O; Bräutigam L; Johansson L; Höglund A; Hagenkort A; Pham T; Altun M; Gaugaz FZ; Vikingsson S; Evers B; Henriksson M; Vallin KS; Wallner OA; Hammarström LG; Wiita E; Almlöf I; Kalderén C; Axelsson H; Djureinovic T; Puigvert JC; Häggblad M; Jeppsson F; Martens U; Lundin C; Lundgren B; Granelli I; Jensen AJ; Artursson P; Nilsson JA; Stenmark P; Scobie M; Berglund UW; Helleday T
Nature; 2014 Apr; 508(7495):215-21. PubMed ID: 24695224
[TBL] [Abstract][Full Text] [Related]
6. Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.
Kettle JG; Alwan H; Bista M; Breed J; Davies NL; Eckersley K; Fillery S; Foote KM; Goodwin L; Jones DR; Käck H; Lau A; Nissink JW; Read J; Scott JS; Taylor B; Walker G; Wissler L; Wylot M
J Med Chem; 2016 Mar; 59(6):2346-61. PubMed ID: 26878898
[TBL] [Abstract][Full Text] [Related]
7. Identification and structure-activity relationship of purine derivatives as novel MTH1 inhibitors.
Kumar A; Kawamura T; Kawatani M; Osada H; Zhang KYJ
Chem Biol Drug Des; 2017 Jun; 89(6):862-869. PubMed ID: 27863017
[TBL] [Abstract][Full Text] [Related]
8. Potent and specific MTH1 inhibitors targeting gastric cancer.
Zhou W; Ma L; Yang J; Qiao H; Li L; Guo Q; Ma J; Zhao L; Wang J; Jiang G; Wan X; Adam Goscinski M; Ding L; Zheng Y; Li W; Liu H; Suo Z; Zhao W
Cell Death Dis; 2019 Jun; 10(6):434. PubMed ID: 31164636
[TBL] [Abstract][Full Text] [Related]
9. Identification of potent and selective MTH1 inhibitors.
Petrocchi A; Leo E; Reyna NJ; Hamilton MM; Shi X; Parker CA; Mseeh F; Bardenhagen JP; Leonard P; Cross JB; Huang S; Jiang Y; Cardozo M; Draetta G; Marszalek JR; Toniatti C; Jones P; Lewis RT
Bioorg Med Chem Lett; 2016 Mar; 26(6):1503-1507. PubMed ID: 26898335
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity.
Peng C; Li YH; Yu CW; Cheng ZH; Liu JR; Hsu JL; Hsin LW; Huang CT; Juan HF; Chern JW; Cheng YS
Bioorg Chem; 2021 May; 110():104813. PubMed ID: 33774493
[TBL] [Abstract][Full Text] [Related]
11. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.
Huber KV; Salah E; Radic B; Gridling M; Elkins JM; Stukalov A; Jemth AS; Göktürk C; Sanjiv K; Strömberg K; Pham T; Berglund UW; Colinge J; Bennett KL; Loizou JI; Helleday T; Knapp S; Superti-Furga G
Nature; 2014 Apr; 508(7495):222-7. PubMed ID: 24695225
[TBL] [Abstract][Full Text] [Related]
12. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening.
Yokoyama T; Kitakami R; Mizuguchi M
Eur J Med Chem; 2019 Apr; 167():153-160. PubMed ID: 30771603
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.
Chen H; Afrin S; Guo Y; Chu W; Benzinger TLS; Rogers BE; Garbow JR; Perlmutter JS; Zhou D; Xu J
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238630
[TBL] [Abstract][Full Text] [Related]
15. MTH1 inhibitor amplifies the lethality of reactive oxygen species to tumor in photodynamic therapy.
Zhao L; Li J; Su Y; Yang L; Chen L; Qiang L; Wang Y; Xiang H; Tham HP; Peng J; Zhao Y
Sci Adv; 2020 Mar; 6(10):eaaz0575. PubMed ID: 32181355
[TBL] [Abstract][Full Text] [Related]
16. Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
Li X; Li L; Huang Y; Liu B; Chi H; Shi L; Zhang W; Li G; Niu Y; Zhu X
Biomater Sci; 2017 Sep; 5(10):2068-2078. PubMed ID: 28744533
[TBL] [Abstract][Full Text] [Related]
17. AuNP flares-capped mesoporous silica nanoplatform for MTH1 detection and inhibition.
Gao W; Cao W; Sun Y; Wei X; Xu K; Zhang H; Tang B
Biomaterials; 2015 Nov; 69():212-21. PubMed ID: 26298289
[TBL] [Abstract][Full Text] [Related]
18. Crystal Structures and Inhibitor Interactions of Mouse and Dog MTH1 Reveal Species-Specific Differences in Affinity.
Narwal M; Jemth AS; Gustafsson R; Almlöf I; Warpman Berglund U; Helleday T; Stenmark P
Biochemistry; 2018 Feb; 57(5):593-603. PubMed ID: 29281266
[TBL] [Abstract][Full Text] [Related]
19. Cancer therapy. Targeting the poison within.
Smits VA; Gillespie DA
Cell Cycle; 2014; 13(15):2330-3. PubMed ID: 25483183
[TBL] [Abstract][Full Text] [Related]
20. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
Shi XL; Li Y; Zhao LM; Su LW; Ding G
Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
